Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENWORTH FINANCIAL INCGNW · Entity 4085 | Director | May 20, 2026 | May 21, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENWORTH FINANCIAL INC
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,728.537 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 31,547 · Balance 163,728.537 F1: Reflects award of restricted stock units (RSUs) in payment of a portion of the reporting person's annual retainer fee. The RSUs vest on the one-year anniversary of the grant date, and convert to shares of Common Stock upon vesting (unless the reporting person elected to defer receipt of the shares until termination of service as a director or to a future specified year). F2: Reflects the twenty-day average trading price per share of Common Stock, which was used to determine the number of RSUs granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects award of restricted stock units (RSUs) in payment of a portion of the reporting person's annual retainer fee. The RSUs vest on the one-year anniversary of the grant date, and convert to shares of Common Stock upon vesting (unless the reporting person elected to defer receipt of the shares until termination of service as a director or to a future specified year).
F2: Reflects the twenty-day average trading price per share of Common Stock, which was used to determine the number of RSUs granted.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,048 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 23,660 · Balance 144,873 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 1,175 · Balance 146,048 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 23,660 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Exercise / conversion · Disposed 1,174.4921 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 74,000 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 39,131 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $31.63 · Expires 2023-05-28 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 6,623 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4: These options vested on May 28, 2014. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.72 · Expires 2024-04-11 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 2,974 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on April 11, 2015. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 2,603 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on May 1, 2016. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 2,788 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on February 17, 2017. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 2,928 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 3, 2018. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 2,984 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 2, 2019. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 4,352 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: These options vested on March 2, 2020. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 6,151 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F11: These options will vest on March 2, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-16 · Disposition to issuer · Disposed 9,440 · Balance 0 F12: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F13: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F4: These options vested on May 28, 2014.
F5: These options vested on April 11, 2015.
F6: These options vested on May 1, 2016.
F7: These options vested on February 17, 2017.
F8: These options vested on March 3, 2018.
F9: These options vested on March 2, 2019.
F10: These options vested on March 2, 2020.
F11: These options will vest on March 2, 2021.
F12: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F13: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
Virgin Orbit Holdings, Inc.
Report date December 29, 2021 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2021-12-29 transaction · row 1
1 source rowRow 1 · 2021-12-29 · Grant · Acquired 125,000 · Balance 125,000 F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 8, 2017 00:27 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | $0.00 Strike: $45.18 | $0.00 |
DisclosureSEC source: 0000899243-17-006755 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 Underlying: Ordinary Shares · 2,928 shares Expires 2027-03-03 F1 · derivative.exercise_date: These options will vest in full on March 3, 2018 and expire on March 3, 2027. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 00:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004814 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 00:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004814 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 20:20 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 6,987.234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143605 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,837.607 Underlying: Class A Common Stock · 6,987.234 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.88 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.